Search

Your search keyword '"de Steur, W"' showing total 21 results
Start Over Author "de Steur, W" Search Limiters Full Text
21 results on '"de Steur, W"'

1. Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial

Author

Keywani, K., Eshuis, W. J., Borgstein, A. B. J., van Det, M. J., van Duijvendijk, P., van Etten, B., Grimminger, P. P., Heisterkamp, J., Lagarde, S. M., Luyer, M. D. P., Markar, S. R., Meijer, S. L., Pierie, J. P. E. N., Roviello, F., Ruurda, J. P., van Sandick, J. W., Sosef, M., Witteman, B. P. L., de Steur, W. O., Lissenberg-Witte, B. I., van Berge Henegouwen, M. I., and Gisbertz, S. S.

Published
2024
Full Text
View/download PDF

3. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study)

Author

Brenkman, H. J. F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., van Lanschot, J. J. B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H. M. B., Hulsewe, K. W. E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C. T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J. T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W. M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W. J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group

Published
2018
Full Text
View/download PDF

4. Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands

Author

Arts Assistenten CTC, MS CGO, Cancer, MS HOD, Luijten, J. C.H.B.M., Nieuwenhuijzen, G. A.P., Sosef, M. N., de Hingh, I. H.J.T., Rosman, C., Ruurda, J. P., van Duijvendijk, P., Heisterkamp, J., de Steur, W. O., van Laarhoven, H. W.M., Besselink, M. G., Groot Koerkamp, B., van Santvoort, H. C., Lemmens, V. E.P., Vissers, P. A.J., Arts Assistenten CTC, MS CGO, Cancer, MS HOD, Luijten, J. C.H.B.M., Nieuwenhuijzen, G. A.P., Sosef, M. N., de Hingh, I. H.J.T., Rosman, C., Ruurda, J. P., van Duijvendijk, P., Heisterkamp, J., de Steur, W. O., van Laarhoven, H. W.M., Besselink, M. G., Groot Koerkamp, B., van Santvoort, H. C., Lemmens, V. E.P., and Vissers, P. A.J.

Published
2022

5. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Author

Kroese, T.E. van Hillegersberg, R. Schoppmann, S. Deseyne, P.R.A.J. Nafteux, P. Obermannova, R. Nordsmark, M. Pfeiffer, P. Hawkings, M.A. Smyth, E. Markar, S. Hanna, G.B. Cheong, E. Chaudry, A. Elme, A. Adenis, A. Piessen, G. Gani, C. Bruns, C.J. Moehler, M. Liakakos, T. Reynolds, J. Morganti, A. Rosati, R. Castoro, C. D'Ugo, D. Roviello, F. Bencivenga, M. de Manzoni, G. Jeene, P. van Sandick, J.W. Muijs, C. Slingerland, M. Nieuwenhuijzen, G. Wijnhoven, B. Beerepoot, L.V. Kolodziejczyk, P. Polkowski, W.P. Alsina, M. Pera, M. Kanonnikoff, T.F. Nilsson, M. Guckenberger, M. Monig, S. Wagner, D. Wyrwicz, L. Berbee, M. Gockel, I. Lordick, F. Griffiths, E.A. Verheij, M. van Rossum, P.S.N. van Laarhoven, H.W.M. Rosman, C. Rütten, H. Gootjes, E.C. Vonken, F.E.M. van Dieren, J.M. Vollebergh, M.A. van der Sangen, M. Creemers, G.-J. Zander, T. Schlößer, H. Cascinu, S. Mazza, E. Nicoletti, R. Damascelli, A. Slim, N. Passoni, P. Cossu, A. Puccetti, F. Barbieri, L. Fanti, L. Azzolini, F. Ventoruzzo, F. Szczepanik, A. Visa, L. Reig, A. Roques, T. Harrison, M. Ciseł, B. Pikuła, A. Skórzewska, M. Vanommeslaeghe, H. Van Daele, E. Pattyn, P. Geboes, K. Callebout, E. Ribeiro, S. van Duijvendijk, P. Tromp, C. Sosef, M. Warmerdam, F. Heisterkamp, J. Vera, A. Jordá, E. López-Mozos, F. Fernandez-Moreno, M.C. Barrios-Carvajal, M. Huerta, M. de Steur, W. Lips, I. Diez, M. Castro, S. O'Neill, R. Holyoake, D. Hacker, U. Denecke, T. Kuhnt, T. Hoffmeister, A. Kluge, R. Bostel, T. Grimminger, P. Jedlička, V. Křístek, J. Pospíšil, P. Mourregot, A. Maurin, C. Starling, N. Chong, I. OMEC working group

Abstract

Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (

Published
2022

6. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer

Author

Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, CCA - Cancer Treatment and Quality of Life, AGEM - Re-generation and cancer of the digestive system, Surgery, Lifelong Learning, Education & Assessment Research Network (LEARN), Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, Lung Neoplasms, Esophageal Neoplasms, SURGERY, medicine.medical_treatment, Kaplan-Meier Estimate, RADICAL ESOPHAGECTOMY, Gastroenterology, Metastasis, COLORECTAL-CANCER, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], hepatic surgery, 0302 clinical medicine, Pulmonary metastasis, Medicine, Registries, Prospective cohort study, Neoadjuvant therapy, Netherlands, Liver Neoplasms, SURGICAL RESECTION, esophageal and gastric cancer, General Medicine, CHEMOTHERAPY, Middle Aged, Combined Modality Therapy, Survival Rate, Treatment Outcome, Esophagectomy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Original Article, Female, Metastasectomy, pulmonary surgery, Erratum, medicine.medical_specialty, CARCINOMA, RECURRENCE PATTERN, Resection, LIVER METASTASES, CHEMORADIOTHERAPY, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Gastrectomy, Stomach Neoplasms, Internal medicine, Carcinoma, metastasis, Humans, Aged, esophageal and gastric surgery, business.industry, Neuroendocrine neoplasm, Cancer, LONG-TERM SURVIVAL, medicine.disease, Surgery, business, Author name, Chemoradiotherapy
Abstract

SUMMARY The standard of care for gastroesophageal cancer patients with hepatic or pulmonary metastases is best supportive care or palliative chemotherapy. Occasionally, patients can be selected for curative treatment instead. This study aimed to evaluate patients who underwent a resection of hepatic or pulmonary metastasis with curative intent. The Dutch national registry for histo- and cytopathology was used to identify these patients. Data were retrieved from the individual patient files. Kaplan–Meier survival analysis was performed. Between 1991 and 2016, 32,057 patients received a gastrectomy or esophagectomy for gastroesophageal cancer in the Netherlands. Of these patients, 34 selected patients received a resection of hepatic metastasis (n = 19) or pulmonary metastasis (n = 15) in 21 different hospitals. Only 4 patients received neoadjuvant therapy before metastasectomy. The majority of patients had solitary, metachronous metastases. After metastasectomy, grade 3 (Clavien–Dindo) complications occurred in 7 patients and mortality in 1 patient. After resection of hepatic metastases, the median potential follow-up time was 54 months. Median overall survival (OS) was 28 months and the 1-, 3-, and 5- year OS was 84%, 41%, and 31%, respectively. After pulmonary metastases resection, the median potential follow-up time was 80 months. The median OS was not reached and the 1-, 3-, and 5- year OS was 67%, 53%, and 53%, respectively. In selected patients with gastroesophageal cancer with hepatic or pulmonary metastases, metastasectomy was performed with limited morbidity and mortality and offered a 5-year OS of 31–53%. Further prospective studies are required.

Published
2020

7. International comparison of treatment strategy and survival in metastatic gastric cancer

Author

Claassen, Y. H. M., Bastiaannet, E., Hartgrink, H. H., Dikken, J. L., de Steur, W. O., Slingerland, M., Verhoeven, R. H. A., van Eycken, E., de Schutter, H., Lindblad, M., Hedberg, Jakob, Johnson, E., Hjortland, G. O., Jensen, L. S., Larsson, H. J., Koessler, T., Chevallay, M., Allum, W. H., van de Velde, C. J. H., Claassen, Y. H. M., Bastiaannet, E., Hartgrink, H. H., Dikken, J. L., de Steur, W. O., Slingerland, M., Verhoeven, R. H. A., van Eycken, E., de Schutter, H., Lindblad, M., Hedberg, Jakob, Johnson, E., Hjortland, G. O., Jensen, L. S., Larsson, H. J., Koessler, T., Chevallay, M., Allum, W. H., and van de Velde, C. J. H.

Abstract

BackgroundIn the randomized Asian REGATTA trial, no survival benefit was shown for additional gastrectomy over chemotherapy alone in patients with advanced gastric cancer with a single incurable factor, thereby discouraging surgery for these patients. The purpose of this study was to evaluate treatment strategies for patients with metastatic gastric cancer in daily practice in five European countries, along with relative survival in each country. MethodsNationwide population-based data from Belgium, Denmark, the Netherlands, Norway and Sweden were combined. Patients with primary metastatic gastric cancer diagnosed between 2006 and 2014 were included. The proportion of gastric resections performed and the administration of chemotherapy (irrespective of surgery) within each country were determined. Relative survival according to country was calculated. ResultsOverall, 15 057 patients with gastric cancer were included. The proportion of gastric resections varied from 81 per cent in the Netherlands and Denmark to 183 per cent in Belgium. Administration of chemotherapy was 392 per cent in the Netherlands, compared with 632 per cent in Belgium. The 6-month relative survival rate was between 390 (95 per cent c.i. 378 to 402) per cent in the Netherlands and 541 (521 to 569) per cent in Belgium. ConclusionThere is variation in the use of gastrectomy and chemotherapy in patients with metastatic gastric cancer, and subsequent differences in survival.

Published
2019
Full Text
View/download PDF

8. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer : a nationwide study

Author

Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, and van Workum, F

Published
2019

9. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study

Author

MS CGO, Cancer, Heelkunde Opleiding, Pathologie Pathologen staf, Divisie Beeld & Oncologie, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, MS CGO, Cancer, Heelkunde Opleiding, Pathologie Pathologen staf, Divisie Beeld & Oncologie, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, and van Workum, F

Published
2019

10. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer : A multicenter prospective study (PLASTIC-study)

Author

Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., on behalf of the PLASTIC Study Group, Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group

Published
2018

11. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: A multicenter prospective study (PLASTIC-study)

Author

MS CGO, Cancer, Divisie Beeld & Oncologie, MS Radiologie, MS Medische Oncologie, Verplegingswetenschap, Other research (not in main researchprogram), JC onderzoeksprogramma Methodologie, HEE, Child Health, Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., on behalf of the PLASTIC Study Group, MS CGO, Cancer, Divisie Beeld & Oncologie, MS Radiologie, MS Medische Oncologie, Verplegingswetenschap, Other research (not in main researchprogram), JC onderzoeksprogramma Methodologie, HEE, Child Health, Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group

Published
2018

12. International comparison of treatment strategy and survival in metastatic gastric cancer

Author

Claassen, Y. H. M., primary, Bastiaannet, E., additional, Hartgrink, H. H., additional, Dikken, J. L., additional, de Steur, W. O., additional, Slingerland, M., additional, Verhoeven, R. H. A., additional, van Eycken, E., additional, de Schutter, H., additional, Lindblad, M., additional, Hedberg, J., additional, Johnson, E., additional, Hjortland, G. O., additional, Jensen, L. S., additional, Larsson, H. J., additional, Koessler, T., additional, Chevallay, M., additional, Allum, W. H., additional, and van de Velde, C. J. H., additional

Published
2018
Full Text
View/download PDF

13. Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial

Author

Claassen, Y. H. M., primary, Hartgrink, H. H., additional, de Steur, W. O., additional, Dikken, J. L., additional, van Sandick, J. W., additional, van Grieken, N. C. T., additional, Cats, A., additional, Trip, A. K., additional, Jansen, E. P. M., additional, Kranenbarg, W. M. Meershoek-Klein, additional, Braak, J. P. B. M., additional, Putter, H., additional, van Berge Henegouwen, M. I., additional, Verheij, M., additional, and van de Velde, C. J. H., additional

Published
2018
Full Text
View/download PDF

14. Description and analysis of clinical pathways for oesophago-gastric adenocarcinoma, in 10 European countries (the EURECCA upper gastro intestinal group - European Registration of Cancer Care)

Author

Messager, M, de Steur, W, Boelens, P G, Jensen, L S, Mariette, C, Reynolds, J V, Osorio, J, Pera, M, Johansson, J, Kołodziejczyk, P, Roviello, F, De Manzoni, G, Moenig, Stefan Paul, Allum, W H, and EURECCA Upper GI group (European Registration of Cancer Care)

Subjects
Endoscopic ultrasound, Time Factors, Esophageal Neoplasms, Denmark, 030230 surgery, Adenocarcinoma / pathology, Adenocarcinoma / therapy, 0302 clinical medicine, Clinical pathway, Multidisciplinary approach, Germany, Surveys and Questionnaires, Registries, Esophageal Neoplasms / pathology, Netherlands, Response rate (survey), Oncologists, medicine.diagnostic_test, ddc:617, Esophageal Neoplasms / therapy, Oesophageal cancer, Health Policy, Esòfag -- Càncer, General Medicine, Europe, Oncology, Italy, 030220 oncology & carcinogenesis, Critical Pathways, EURECCA, France, medicine.medical_specialty, National health policy, Audit, Stomach Neoplasms / diagnosis, Adenocarcinoma, 03 medical and health sciences, Adenocarcinoma / diagnosis, Stomach Neoplasms, Patient experience, medicine, Animals, Humans, Intensive care medicine, Health policy, Neoplasm Staging, Quality of Health Care, Patient Care Team, Surgeons, Sweden, Esophageal Neoplasms / diagnosis, Care pathway, business.industry, Gastroenterologists, Cancer, medicine.disease, United Kingdom, Surgery, Spain, Poland, Stomach Neoplasms / therapy, business, Gastric cancer, Stomach Neoplasms / pathology, Ireland
Abstract

AIMS: Outcomes for patients with oesophago-gastric cancer are variable across Europe. The reasons for this variability are not clear. The aim of this study was to describe and analyse clinical pathways to understand differences in service provision for oesophageal and gastric cancer in the countries participating in the EURECCA Upper GI group. METHODS: A questionnaire was devised to assess clinical presentation, diagnosis, staging, treatment, pathology, follow-up and service frameworks across Europe for patients with oesophageal and gastric cancer. The questionnaire was issued to experts from 14 countries. The responses were analysed quantitatively and qualitatively and compared. RESULTS: The response rate was (10/14) 71.4%. The approach to diagnosis was similar. Most countries established a diagnosis within 3 weeks of presentation. However, there were different approaches to staging with variable use of endoscopic ultrasound reflecting availability. There has been centralisation of treatments in most countries for oesophageal surgery. The most consistent area was the approach to pathology. There were variations in access to specialist nurse and dietitian support. Although most countries have multidisciplinary teams, their composition and frequency of meetings varied. The two main areas of significant difference were research and audit and overall service provision. Observations on service framework indicated that limited resources restricted many of the services. CONCLUSION: The principle approaches to diagnosis, treatment and pathology were similar. Factors affecting the quality of patient experience were variable. This may reflect availability of resources. Standard pathways of care may enhance both the quality of treatment and patient experience. The 2013 Annual Grant for international mobility from the AFC (French Association of Surgery) was part of the salary of MM.

Published
2016

15. Description and analysis of clinical pathways for oesophago-gastric adenocarcinoma, in 10 European countries (the EURECCA upper gastro intestinal group - European Registration of Cancer Care)

Author

Messager, M., de Steur, W., Boelens, P. G., Jensen, L. S., Marlette, C., Reynolds, J. V., Osorio, J., Pera, M., Johansson, J., Kolodziejczyk, P., Roviello, F., De Manzoni, G., Moenig, S. P., Allum, W. H., Messager, M., de Steur, W., Boelens, P. G., Jensen, L. S., Marlette, C., Reynolds, J. V., Osorio, J., Pera, M., Johansson, J., Kolodziejczyk, P., Roviello, F., De Manzoni, G., Moenig, S. P., and Allum, W. H.

Abstract

Aims: Outcomes for patients with oesophago-gastric cancer are variable across Europe. The reasons for this variability are not clear. The aim of this study was to describe and analyse clinical pathways to understand differences in service provision for oesophageal and gastric cancer in the countries participating in the EURECCA Upper GI group. Methods: A questionnaire was devised to assess clinical presentation, diagnosis, staging, treatment, pathology, follow-up and service frameworks across Europe for patients with oesophageal and gastric cancer. The questionnaire was issued to experts from 14 countries. The responses were analysed quantitatively and qualitatively and compared. Results: The response rate was (10/14) 71.4%. The approach to diagnosis was similar. Most countries established a diagnosis within 3 weeks of presentation. However, there were different approaches to staging with variable use of endoscopic ultrasound reflecting availability. There has been centralisation of treatments in most countries for oesophageal surgery. The most consistent area was the approach to pathology. There were variations in access to specialist nurse and dietitian support. Although most countries have multidisciplinary teams, their composition and frequency of meetings varied. The two main areas of significant difference were research and audit and overall service provision. Observations on service framework indicated that limited resources restricted many of the services. Conclusion: The principle approaches to diagnosis, treatment and pathology were similar. Factors affecting the quality of patient experience were variable. This may reflect availability of resources. Standard pathways of care may enhance both the quality of treatment and patient experience. (C) 2016 Elsevier Ltd. All rights reserved.

Published
2016

16. Esophageal and Gastric Cancer Pearl : a nationwide clinical biobanking project in the Netherlands

Author

Haverkamp, L, Parry, K, van Berge Henegouwen, M I, van Laarhoven, H W, Bonenkamp, J J, Bisseling, T M, Siersema, P D, Sosef, M N, Stoot, J H, Beets, G L, de Steur, W O, Hartgrink, H H, Verspaget, H W, van der Peet, D L, Plukker, J T, van Etten, B, Wijnhoven, B P L, van Lanschot, J J, van Hillegersberg, R, Ruurda, J P, Haverkamp, L, Parry, K, van Berge Henegouwen, M I, van Laarhoven, H W, Bonenkamp, J J, Bisseling, T M, Siersema, P D, Sosef, M N, Stoot, J H, Beets, G L, de Steur, W O, Hartgrink, H H, Verspaget, H W, van der Peet, D L, Plukker, J T, van Etten, B, Wijnhoven, B P L, van Lanschot, J J, van Hillegersberg, R, and Ruurda, J P

Published
2015

17. Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands

Author

MS CGO, MS MDL 1, Infection & Immunity, Cancer, MS MDL Oncologie, Divisie Beeld & Oncologie, Other research (not in main researchprogram), Haverkamp, L, Parry, K, van Berge Henegouwen, M I, van Laarhoven, H W, Bonenkamp, J J, Bisseling, T M, Siersema, P D, Sosef, M N, Stoot, J H, Beets, G L, de Steur, W O, Hartgrink, H H, Verspaget, H W, van der Peet, D L, Plukker, J T, van Etten, B, Wijnhoven, B P L, van Lanschot, J J, van Hillegersberg, R, Ruurda, J P, MS CGO, MS MDL 1, Infection & Immunity, Cancer, MS MDL Oncologie, Divisie Beeld & Oncologie, Other research (not in main researchprogram), Haverkamp, L, Parry, K, van Berge Henegouwen, M I, van Laarhoven, H W, Bonenkamp, J J, Bisseling, T M, Siersema, P D, Sosef, M N, Stoot, J H, Beets, G L, de Steur, W O, Hartgrink, H H, Verspaget, H W, van der Peet, D L, Plukker, J T, van Etten, B, Wijnhoven, B P L, van Lanschot, J J, van Hillegersberg, R, and Ruurda, J P

Published
2015

19. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Author

Tiuri E. Kroese, Richard van Hillegersberg, Sebastian Schoppmann, Pieter R.A.J. Deseyne, Philippe Nafteux, Radka Obermannova, Marianne Nordsmark, Per Pfeiffer, Maria A. Hawkins, Elizabeth Smyth, Sheraz Markar, George B. Hanna, Edward Cheong, Asif Chaudry, Anneli Elme, Antoine Adenis, Guillaume Piessen, Cihan Gani, Christiane J. Bruns, Markus Moehler, Theodore Liakakos, John Reynolds, Alessio Morganti, Riccardo Rosati, Carlo Castoro, Domenico D'Ugo, Franco Roviello, Maria Bencivenga, Giovanni de Manzoni, Paul Jeene, Johanna W. van Sandick, Christel Muijs, Marije Slingerland, Grard Nieuwenhuijzen, Bas Wijnhoven, Laurens V. Beerepoot, Piotr Kolodziejczyk, Wojciech P. Polkowski, Maria Alsina, Manuel Pera, Tania F. Kanonnikoff, Magnus Nilsson, Matthias Guckenberger, Stefan Monig, Dorethea Wagner, Lucjan Wyrwicz, Maaike Berbee, Ines Gockel, Florian Lordick, Ewen A. Griffiths, Marcel Verheij, Peter S.N. van Rossum, Hanneke W.M. van Laarhoven, Camiel Rosman, Heide Rütten, Elske C. Gootjes, Francine E.M. Vonken, Jolanda M. van Dieren, Marieke A. Vollebergh, Maurice van der Sangen, Geert-Jan Creemers, Thomas Zander, Hans Schlößer, Stefano Cascinu, Elena Mazza, Roberto Nicoletti, Anna Damascelli, Najla Slim, Paolo Passoni, Andrea Cossu, Francesco Puccetti, Lavinia Barbieri, Lorella Fanti, Francesco Azzolini, Federico Ventoruzzo, Antoni Szczepanik, Laura Visa, Anna Reig, Tom Roques, Mark Harrison, Bogumiła Ciseł, Agnieszka Pikuła, Magdalena Skórzewska, Hanne Vanommeslaeghe, Elke Van Daele, Piet Pattyn, Karen Geboes, Eduard Callebout, Suzane Ribeiro, Peter van Duijvendijk, Cathrien Tromp, Meindert Sosef, Fabienne Warmerdam, Joos Heisterkamp, Almudena Vera, Esther Jordá, Fernando López-Mozos, Maria C. Fernandez-Moreno, Maria Barrios-Carvajal, Marisol Huerta, Wobbe de Steur, Irene Lips, Marc Diez, Sandra Castro, Robert O'Neill, Daniel Holyoake, Ulrich Hacker, Timm Denecke, Thomas Kuhnt, Albrecht Hoffmeister, Regine Kluge, Tilman Bostel, Peter Grimminger, Václav Jedlička, Jan Křístek, Petr Pospíšil, Anne Mourregot, Clotilde Maurin, Naureen Starling, Irene Chong, Institut Català de la Salut, [Kroese TE] Department of Surgery, Utrecht University Medical Center, Utrecht University, Utrecht, the Netherlands. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [van Hillegersberg R] Department of Surgery, Utrecht University Medical Center, Utrecht University, Utrecht, the Netherlands. [Schoppmann S] Department of Surgery, Medical University of Vienna, Vienna University, Vienna, Austria. [Deseyne PRAJ] Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. [Nafteux P] Department of Surgery, KU Leuven, Leuven University, Leuven, Belgium. [Obermannova R] Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. [Alsina M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Radiotherapie, MUMC+: MA Radiotherapie OC (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Radiation Oncology, AII - Cancer immunology, CCA - Cancer biology and immunology, Internal medicine, Surgery, Kroese, T. E., van Hillegersberg, R., Schoppmann, S., Deseyne, P. R. A. J., Nafteux, P., Obermannova, R., Nordsmark, M., Pfeiffer, P., Hawkings, M. A., Smyth, E., Markar, S., Hanna, G. B., Cheong, E., Chaudry, A., Elme, A., Adenis, A., Piessen, G., Gani, C., Bruns, C. J., Moehler, M., Liakakos, T., Reynolds, J., Morganti, A., Rosati, R., Castoro, C., D'Ugo, D., Roviello, F., Bencivenga, M., de Manzoni, G., Jeene, P., van Sandick, J. W., Muijs, C., Slingerland, M., Nieuwenhuijzen, G., Wijnhoven, B., Beerepoot, L. V., Kolodziejczyk, P., Polkowski, W. P., Alsina, M., Pera, M., Kanonnikoff, T. F., Nilsson, M., Guckenberger, M., Monig, S., Wagner, D., Wyrwicz, L., Berbee, M., Gockel, I., Lordick, F., Griffiths, E. A., Verheij, M., van Rossum, P. S. N., van Laarhoven, H. W. M., Rosman, C., Rutten, H., Gootjes, E. C., Vonken, F. E. M., van Dieren, J. M., Vollebergh, M. A., van der Sangen, M., Creemers, G. -J., Zander, T., Schlosser, H., Cascinu, S., Mazza, E., Nicoletti, R., Damascelli, A., Slim, N., Passoni, P., Cossu, A., Puccetti, F., Barbieri, L., Fanti, L., Azzolini, F., Ventoruzzo, F., Szczepanik, A., Visa, L., Reig, A., Roques, T., Harrison, M., Cisel, B., Pikula, A., Skorzewska, M., Vanommeslaeghe, H., Van Daele, E., Pattyn, P., Geboes, K., Callebout, E., Ribeiro, S., van Duijvendijk, P., Tromp, C., Sosef, M., Warmerdam, F., Heisterkamp, J., Vera, A., Jorda, E., Lopez-Mozos, F., Fernandez-Moreno, M. C., Barrios-Carvajal, M., Huerta, M., de Steur, W., Lips, I., Diez, M., Castro, S., O'Neill, R., Holyoake, D., Hacker, U., Denecke, T., Kuhnt, T., Hoffmeister, A., Kluge, R., Bostel, T., Grimminger, P., Jedlicka, V., Kristek, J., Pospisil, P., Mourregot, A., Maurin, C., Starling, N., Chong, I., Oncology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Cancer Research, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias gástricas [ENFERMEDADES], Neoplasm metastasis, Radiosurgery, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], SDG 3 - Good Health and Well-being, Metàstasi, Neoplasms, Medicine and Health Sciences, Humans, Mastectomia, Oligometastasis, SURGICAL RESECTION, Metastasectomy, Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Aparell digestiu - Càncer - Cirurgia, CHEMOTHERAPY, Europe, Surgical Procedures, Operative::Metastasectomy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], intervenciones quirúrgicas::metastasectomía [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Oncology, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], JUNCTION, Gastric neoplasm, SURVIVAL, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms [DISEASES], Lymph Nodes, Oesophageal neoplasm
Abstract

Oesophageal neoplasm; Oligometastasis; Radiosurgery Neoplàsia esofàgica; Oligometàstasi; Radiocirurgia Neoplasia esofágica; Oligometástasis; Radiocirugía Background Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (

Published
2022

20. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.

Author

de Steur WO, van Amelsfoort RM, Hartgrink HH, Putter H, Meershoek-Klein Kranenbarg E, van Grieken NCT, van Sandick JW, Claassen YHM, Braak JPBM, Jansen EPM, Sikorska K, van Tinteren H, Walraven I, Lind P, Nordsmark M, van Berge Henegouwen MI, van Laarhoven HWM, Cats A, Verheij M, and van de Velde CJH

Subjects
Chemotherapy, Adjuvant, Humans, Netherlands epidemiology, Sweden, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Adjuvant, Stomach Neoplasms drug therapy, Stomach Neoplasms surgery
Abstract

Background: The Intergroup 0116 and the MAGIC trials changed clinical practice for resectable gastric cancer in the Western world. In these trials, overall survival improved with post-operative chemoradiotherapy (CRT) and perioperative chemotherapy (CT). Intention-to-treat analysis in the CRITICS trial of post-operative CT or post-operative CRT did not show a survival difference. The current study reports on the per-protocol (PP) analysis of the CRITICS trial., Patients and Methods: The CRITICS trial was a randomized, controlled trial in which 788 patients with stage Ib-Iva resectable gastric or esophagogastric adenocarcinoma were included. Before start of preoperative CT, patients from the Netherlands, Sweden and Denmark were randomly assigned to receive post-operative CT or CRT. For the current analysis, only patients who started their allocated post-operative treatment were included. Since it is uncertain that the two treatment arms are balanced in such PP analysis, adjusted proportional hazards regression analysis and inverse probability weighted analysis were used to minimize the risk of selection bias and to estimate and compare overall and event-free survival., Results: Of the 788 patients, 478 started post-operative treatment according to protocol, 233 (59%) patients in the CT group and 245 (62%) patients in the CRT group. Patient and tumor characteristics between the groups before start of the post-operative treatment were not different. After a median follow-up of 6.7 years since the start of post-operative treatment, the 5-year overall survival was 57.9% (95% confidence interval: 51.4% to 64.3%) in the CT group versus 45.5% (95% confidence interval: 39.2% to 51.8%) in the CRT group (adjusted hazard ratio CRT versus CT: 1.62 (1.24-2.12), P = 0.0004). Inverse probability weighted analysis resulted in similar hazard ratios., Conclusion: After adjustment for all known confounding factors, the PP analysis of patients who started the allocated post-operative treatment in the CRITICS trial showed that the CT group had a significantly better 5-year overall survival than the CRT group (NCT00407186)., Competing Interests: Disclosure MIVBH reports grants from Olympus and Stryker; personal fees from Johnson and Johnson, Medtronic, Mylan and Alesi Surgical. All fees paid to institution outside the submitted work. All remaining authors have declared no conflicts of interest., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

21. The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer.

Author

van Pelt GW, Krol JA, Lips IM, Peters FP, van Klaveren D, Boonstra JJ, de Steur WO, Tollenaar RAEM, Farina Sarasqueta A, Mesker WE, and Slingerland M

Abstract

Background and Purpose: With currently available techniques, the prediction of pathologic complete response after neoadjuvant chemoradiotherapy is insufficient. The tumor-stroma ratio (TSR) has proven to be a predictor of survival for several types of cancer, including esophageal. The aim of this study was to investigate the value of TSR in predicting pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer patients., Materials and Methods: Patients with esophageal adenocarcinoma or squamous cell carcinoma who received neoadjuvant chemoradiotherapy followed by a resection were selected. Haematoxylin and eosin (H&E) stained sections of diagnostic biopsies were collected and TSR was independently assessed by two investigators. Patients were categorized in stroma-low (≤50% stroma) and stroma-high (>50% stroma) groups for further analyses. The tumor regression grade (TRG) was assessed on H&E stained sections of the resected primary tumor to determine pathologic response., Results: A total of 94 patients were included in this study, of which 76 patients were categorized as stroma-low and 18 as stroma-high. Forty-two (45%) patients had a major pathologic response (TRG 1-2), whereas 52 (55%) were considered non-responders. After adjustment for gender, tumor type, cT-status and differentiation grade, patients with a stroma-high tumor showed a higher chance of no response compared to patients with a stroma-low tumor (OR 3.57, 95%CI 1.03-12.31, P  = 0.04)., Conclusion: TSR showed to have the potential to aid in the prediction of pathologic response in esophageal cancer patients receiving neoadjuvant chemoradiotherapy. Larger validation studies are necessary before implementing this method in daily practice., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2019 The Author(s).)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results